Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

PURPOSE: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHOD...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Motzer, Robert J., Nosov, Dmitry, Eisen, Timothy, Bondarenko, Igor, Lesovoy, Vladimir, Lipatov, Oleg, Tomczak, Piotr, Lyulko, Oleksiy, Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alekseev, Boris Y., Sternberg, Cora N., Szczylik, Cezary, Cella, David, Ivanescu, Cristina, Krivoshik, Andrew, Strahs, Andrew, Esteves, Brooke, Berkenblit, Anna, Hutson, Thomas E.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2013
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569677/
https://ncbi.nlm.nih.gov/pubmed/24019545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.4940
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker